BIOTEST BIOTECH announced that the operating revenue for 2024 is 559 million yuan, a year-on-year increase of 26.53%. The net profit attributable to shareholders of the listed company is 170 million yuan, a year-on-year increase of 59.01%. The basic earnings per share is 1.61 yuan/share, a year-on-year increase of 61.00%. The company plans to distribute a cash dividend of 10 yuan for every 10 shares to all shareholders, and to convert 4 shares for every 10 shares from the capital reserve, with no bonus shares issued